comisión mixta - boletín nº 9914-11 (ley fármacos ii) - 13 de noviembre 2024
Published 2 days ago • 170 plays • Length 20:28Download video MP4
Download video MP3
Similar videos
-
0:45
bc300 semi-auto biochemistry analyzer
-
2:27
ascembl: asciminib versus bosutinib in third-line treatment of cp-cml
-
0:40
beat-meso: phase iii trial of bevacizumab and chemo ± atezolizumab for advanced pleural mesothelioma
-
1:14
phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
-
3:30
sc vs. iv administration of a bcma-cd3 bispecific antibody for r/r myeloma
-
1:17
ponatinib versus ascimininib in the third-line treatment of cml
-
1:08:24
ccf webinar: within normal limits-understanding your laboratory blood tests
-
3:10
semple round biochemistry analyser cl-960i
-
3:39:42
cardiologia - banqueo selecto - myc
-
1:07:21
ccf webinar: how "liquid biopsies" are helping with precision medicine for patients with cancer
-
0:48
targeting c/ebpβ in melanoma
-
9:57
teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
-
2:49
gelita spon® rapid³
-
4:46
targeting b-cell receptor signaling in lymphoid malignancies
-
1:06
leonidas tsiokas: "regulation of casr by trpc1 channels"
-
4:03
rationale-306: tislelizumab and chemotherapy in escc
-
1:50
the enzyme trim3 facilitates estrogen signaling and modulates breast cancer progression
-
5:28
regn5459, a bcma×cd3 bispecific antibody, in r/r multiple myeloma
-
1:29
bispecific bcma-cd3 antibody teclistamab is efficacious and tolerable in r/r mm
-
9:50
impact of adding bevacizumab to presurgery chemo for 3n bc varies with subtype
-
0:56
dr. bekaii-saab on tolerability of encorafenib, binimetinib, and cetuximab in braf crc